GE HealthCare Technologies Inc.

The global disposable medical device sensors market is projected to grow from USD 11.86 billion in 2026 to USD 16.13 billion by 2031, a compound annual growth rate of 6.4%, according to a new ResearchAndMarkets.com report. Growth is driven by the rising prevalence of chronic and infectious diseases, remote patient monitoring, point-of-care diagnostics, wearable devices, home healthcare, and infection-prevention needs. By type, biosensors currently hold the largest share of the market, while strip sensors are expected to capture the largest share over the forecast period. The United States is expected to record the highest CAGR within North America, supported by advanced healthcare infrastructure and high adoption of innovative medical technologies. Key players profiled include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Medtronic, and GE HealthCare Technologies Inc.

GE HealthCare and AsiaMedic announced that AsiaMedic is the first site in ASEAN, and among the earliest adopters in Asia Pacific, to implement MR31, the latest generation of GE HealthCare's MRI platform, expanding the range of complex imaging examinations available at its imaging centre in Singapore. MR31 combines deep learning technologies that shorten acquisition times and support detailed examinations across neurological, musculoskeletal and nerve imaging, with Sonic DL for 3D applying deep learning acceleration to 3D volumetric imaging to deliver up to 12 times scan acceleration and reduce scan times across brain, spine, orthopaedic and body examinations. The platform also supports prostate MRI, where AIR Recon DL Phase Correction for advanced diffusion-weighted imaging can provide improved visualization of clinically significant lesions and high-resolution T2-weighted imaging may help benefit lesion localization for prostate fusion biopsy planning. Dr Low Kah Boon, Consultant Radiologist in Abdominal and Pelvic Imaging at AsiaMedic, said Deep Learning-Phase Correction for prostate diffusion-weighted imaging has the potential to improve image quality and diagnostic confidence while supporting a more efficient imaging workflow. Dede Yan, General Manager, SEA6 at GE HealthCare, said adopting a new MRI platform first in a region takes confidence and that AsiaMedic has consistently been willing to invest early in technology that benefits patients.

GE HealthCare Technologies declared a quarterly dividend of $0.04 per share, a 14.3% increase from its prior dividend of $0.035. The new dividend carries a forward yield of 0.24%. It is payable Nov. 13 to shareholders of record as of Oct. 23, with an ex-dividend date of Oct. 23. The increase follows seven consecutive quarters in which the company paid a quarterly dividend of $0.035.

HSBC downgraded Netflix to Hold from Buy with a price target of $76, down from $96, citing Alphabet's YouTube taking increasing viewer share from the streaming giant. The call headlines Wall Street's most market-moving research, which also saw Jefferies downgrade both Valero to Hold from Buy with a $401 price target and Marathon Petroleum to Hold from Buy with a $413 price target, while Morgan Stanley cut Ericsson to Underweight from Equal Weight with a price target of $9, down from $11. Among upgrades, Northcoast raised Brinker to Buy from Neutral with a $275 price target, Piper Sandler lifted MetLife to Overweight from Neutral with a price target of $110, up from $99, and Citi upgraded Fifth Third to Buy from Neutral with a price target of $62, up from $59. In initiations, Rosenblatt started SanDisk at Buy with a $2,400 price target, Needham began GE HealthCare at Buy with a $93 price target, and RBC Capital launched Everest Group at Outperform with a $455 price target. William Blair downgraded Endava to Underperform from Market Perform, and Northcoast cut ACV Auctions to Neutral from Buy after the company agreed to be acquired by Copart for $10.50 per share in cash.

Novo Nordisk will shorten its name to Novo and update its logo, with its trademark bull shifting to face right, as the Danish drugmaker battles Eli Lilly for dominance in the obesity-drug market. CEO Mike Doustdar is pushing to make Novo leaner and more competitive, and the company will detail its updated corporate strategy at a Capital Markets Day on September 21 in London. Separately, Eli Lilly said the U.S. FDA granted full approval for an all-oral regimen combining its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for adults with estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation whose disease progressed after one or more prior endocrine therapies. GE HealthCare Technologies is in advanced talks to acquire Sofie Biosciences for about $1 billion, a deal that would expand its presence in radioactive diagnostic agents used with medical scans, according to the Financial Times. Summit Therapeutics said ivonescimab reduced the risk of death by 27% versus Merck's Keytruda in a late-stage lung cancer trial, with median overall survival of 30.8 months versus 22.6 months. Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group, allowing shareholders to exchange ordinary shares for MiniMed common stock at a 7% discount.

GE HealthCare Technologies Inc. has submitted its next-generation StarGuide GX digital 4D CZT SPECT/CT system to the FDA for 510(k) clearance, following recent CE Mark approval in Europe. The system, designed to support theranostics and precision care, aims to expand access to molecular imaging technologies. Jean-Luc Procaccini, president and CEO of Molecular Imaging and Computed Tomography at GE HealthCare, emphasized the company's focus on innovation to meet evolving healthcare needs. Following the announcement, GEHC stock fell 3% at yesterday's close, and year to date shares are down 18.6%, compared with the industry's 20.6% decline, while the S&P 500 has risen 11.6%. The regulatory progress could strengthen GE HealthCare's position in the molecular imaging market, which is projected to reach $9.5 billion by 2026 with a CAGR of 4.6% through 2030, according to Grand View Research.

MarketsandMarkets projects the global MRI systems market will grow from USD 6.88 billion in 2026 to USD 9.68 billion by 2031, at a CAGR of 7.0%. Growth is driven by the rising prevalence of neurological and musculoskeletal disorders, an expanding geriatric population, increasing chronic diseases like cancer, and supportive regulatory and reimbursement policies. The closed MRI systems segment held the largest market share in 2025, as did the fixed/stationary design segment. Asia Pacific is experiencing rapid growth, particularly in China, India, and Southeast Asia. Key players include Siemens Healthineers, GE HealthCare, Philips, FUJIFILM, and Canon, with innovations focusing on AI-enabled workflows and helium-free systems.

GE HealthCare Technologies Inc. announced that its Photonova Spectra photon-counting CT system has received CE Mark, expanding access to the technology across Europe and other CE Mark-observing markets, following FDA 510(k) clearance and Japanese regulatory approval in March 2026. The system, powered by GEHC's proprietary Deep Silicon detector technology, offers ultra-high-definition imaging and on-demand spectral and spatial imaging. The CE Mark broadens GEHC's commercial opportunity in the photon-counting CT market, which is valued at $0.5 billion in 2026 and expected to grow at a CAGR of 29.4% through 2035. GEHC stock has fallen 1.1% since the announcement, and year to date it is down 14.2%, compared with the industry's 17% decline. The company is also collaborating with UZ Brussel – Vrije Universiteit Brussel and Rigshospitalet to evaluate the system's clinical applications.

The global cardiovascular ultrasound system market is projected to grow from $1.73 billion in 2025 to $1.89 billion in 2026, a compound annual growth rate of 9.8%, and is forecast to reach $2.77 billion by 2030 at a CAGR of 10%, according to a new report from ResearchAndMarkets.com. Growth is driven by rising cardiovascular disease prevalence, demand for early non-invasive diagnostics, and adoption of AI-assisted imaging and portable devices. North America was the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region. Key developments include Royal Philips' August 2025 launch of Transcend Plus for its EPIQ CVx and Affiniti CVx systems, featuring FDA-cleared AI, and Philips' May 2023 acquisition of DiA Imaging Analysis for approximately $100 million to bolster AI-driven cardiac analysis. The report profiles major players including GE HealthCare, Siemens Healthineers, and Koninklijke Philips.

GE HealthCare Technologies Inc. has announced three additions to its Vivid cardiovascular ultrasound portfolio—Vivid Explorer, Vivid Advanced, and Vivid Focus—designed to support cardiac imaging across different care settings, showcased at the European Society of Cardiology Congress 2026 in Munich. The new systems, built on the same technology foundation as Vivid Pioneer, aim to address the distinct needs of echo labs, cardiology practices, and interventional settings while delivering a consistent user experience. Vivid Explorer targets high-volume echo labs with 4D and AI features, Vivid Advanced serves mid-size hospitals with comprehensive imaging, and Vivid Focus brings cSound technology to everyday cardiac imaging. The portfolio also includes the portable Vivid iq, and all systems feature AI-enabled tools like AI Auto Measure 2D and Easy AutoEF to simplify cardiac measurements. GE HealthCare also introduced EchoPAC Software Only v211 for remote or on-site review, with CE Mark received and FDA clearance pending. The global cardiovascular ultrasound market is projected to reach $3.40 billion in 2026, growing at a CAGR of 4.7% through 2033, driven by rising cardiovascular disease prevalence and demand for non-invasive diagnostics. GEHC stock has fallen 1% since the announcement and is down 12.6% year to date, while the S&P 500 has risen 12.2%.

Leo Cancer Care, a pioneer in upright radiation therapy, announced a commercial collaboration with GE HealthCare to integrate advanced imaging and Intelligent Radiation Therapy software with its future upright treatment system. The non-exclusive agreement aims to address challenges in radiation oncology, including multivendor environments, fragmented workflows, and uneven access to technology. The companies will explore connecting GE HealthCare's AI-supported iRT software with Leo Cancer Care's upright solution to streamline workflows and reduce time from imaging to treatment. Ben Newton, Global Head of Oncology at GE HealthCare, and Leo Cancer Care CEO Stephen Towe both highlighted the potential for a more connected, patient-centered model of care.

GE HealthCare Technologies reported second-quarter organic orders rose 11.1% year over year, with book-to-bill reaching 1.15 times and backlog climbing to a record $23.9 billion. Management said order growth was broad based across every segment with no material one-time items, and the two-year order-growth stack exceeded 7%. Nearly 85% of equipment revenue entering the third quarter was already secured, and the company reaffirmed full-year organic revenue growth guidance of 3% to 4%. Some of the strongest order growth came from longer-cycle radiology products expected to contribute more meaningfully to revenues in 2027, while Patient Care Solutions revenues declined 13.3% year over year with negative segment EBIT due to operational and fulfillment challenges.

GE HealthCare introduced the LOGIQ e Xi and LOGIQ e Si laptop ultrasound systems and launched the Invenia ABUS Prime and ABUS StreamVue breast imaging solutions earlier this month, expanding its AI-enabled and cloud-connected ultrasound portfolio across multiple care settings. The launches aim to standardize imaging workflows, support remote reading, and address dense-breast screening needs, potentially strengthening GE HealthCare's position in high-value, technologically advanced diagnostics. The new products slot directly into the company's Imaging and Advanced Visualization Solutions segment, tying into an existing catalyst around expanding recurring digital revenue. How much these launches ultimately matter will depend on adoption, pricing discipline, and whether they help offset ongoing tariff and supply chain headwinds. GE HealthCare's narrative projects $24.3 billion revenue and $2.6 billion earnings by 2029, requiring 4.6% yearly revenue growth and about a $0.6 billion earnings increase from $2.0 billion today.

The global AI-enabled imaging modalities market is projected to grow from $3.41 billion in 2025 to $17.84 billion by 2036, at a compound annual growth rate of 16.24%, according to a new report from ResearchAndMarkets.com. The computed tomography segment is expected to dominate by modality, driven by AI integration for image reconstruction, dose optimization, and automated detection in high-volume settings. North America is forecast to lead regionally due to advanced infrastructure and strong adoption of AI-integrated platforms. Key players include GE HealthCare, Siemens Healthineers, Koninklijke Philips, Canon, and Fujifilm, with recent developments such as GE's FDA clearance for AI-guided radiation planning and Canon's deep-learning CT launch.

U.S. stock futures were broadly higher on Wednesday as Shopify jumped 26% in premarket trading after reporting second-quarter revenue of $3.58 billion, topping analysts' expectations of $3.45 billion, while Advanced Micro Devices fell 8.8% after its revenue outlook disappointed investors. Shopify's adjusted earnings per share of $0.42 also beat estimates, and gross merchandise volume rose 32% from a year earlier with free cash flow climbing to $654 million. AMD's decline was compounded by SpaceX announcing it would build its computing infrastructure exclusively with Nvidia chips, underscoring the challenges AMD faces in winning major AI customers. Among other movers, Eli Lilly gained 5.7% after raising its full-year revenue guidance, GE HealthCare advanced 12.3% on a second-quarter beat, and Disney rose 4.7% after a strong profit beat and plans to repurchase $9 billion of shares in fiscal 2026. On the downside, Pinterest fell 9% on a slower third-quarter revenue outlook, Match Group declined 10.2% after forecasting another drop in paying users, and wireless carriers Verizon and AT&T each fell more than 2% after SpaceX outlined plans for a nationwide mobile service that could compete directly with them.

The global AI in medical imaging market is projected to grow from USD 2.9 billion in 2025 to USD 19.4 billion by 2035, at a compound annual growth rate of 20.9%, according to a new report by Healthcare Foresights. The market is expected to reach USD 3.5 billion in 2026, driven by a shortage of radiologists, high imaging volumes, and the need for faster clinical decision-making. Key growth factors include advancements in deep learning algorithms, increasing adoption of digital health technologies, and supportive regulatory approvals for AI-powered tools. North America is forecast to grow at a CAGR of 16.7%, while the Asia Pacific region is experiencing the highest growth due to rapid digital health transformation and expanding medical imaging infrastructure. Prominent players in the market include GE HealthCare Technologies, Siemens Healthineers, Koninklijke Philips, and Canon Medical Systems.

Wattanapat Hospital Plc is moving forward with investment in importing a 394-slice high-speed computed tomography scanner featuring the AI Revolution™ Maxima innovation from GE HealthCare, aiming to enhance medical diagnostic capabilities. The company is also developing a cross-border emergency patient referral system along the Udon Thani–Nong Khai–Vientiane route, which can cut critical time by over 50%. Dr. Natthira Tangsuebkul, Chief Financial Officer, stated that the AI Auto-Positioning technology will increase daily patient throughput and deliver high-resolution diagnostic images under the principle of patient safety as the top priority. Meanwhile, the referral network in collaboration with Alliance International Medical Centre and Nong Khai Wattana Hospital enables emergency vehicles to reach patients in Vientiane within 10 to 20 minutes and transport them to Udon Thani within 1.5 to 2 hours, down from a previous total of 4 hours. The company is also investing in developing critical pediatric care personnel to international standards and expanding training to partner hospitals in the region, driving towards becoming a sustainable medical hub in the Mekong basin.

GE HealthCare Technologies reported second-quarter fiscal 2026 revenue of $5.30 billion, beating analyst estimates of $5.27 billion and growing 5.8% year on year, while adjusted earnings per share of $1.13 surpassed the consensus of $1.04 by 9.1%. Organic revenue rose 3.5% year on year, driven by robust orders growth particularly in Pharmaceutical Diagnostics and Advanced Imaging Solutions, with total orders up 11% and backlog reaching a record $23.9 billion. Management reiterated full-year adjusted EPS guidance of $4.90 at the midpoint and highlighted the impact of new product launches and expanding recurring service revenues, though Patient Care Solutions faced operational fulfillment headwinds and is undergoing a strategic review that could include divestiture. The company is advancing its innovation pipeline with upcoming launches like Photonova Spectra photon-counting CT and the ramp-up of Flyrcado, which targets $500 million in annual revenue by 2028.

US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.3%, as investors weigh interest rate risks against mixed economic signals. The 10-year US Treasury yield is holding near 4.62%, and markets see roughly a 1 in 3 chance of a rate hike at the upcoming Federal Reserve meeting, with odds for September even higher. Housing data show prices rising only modestly once inflation is taken out. Among top movers, Garmin jumped 16.23% after Q2 results and higher full-year 2026 revenue guidance, GE HealthCare Technologies gained 12.15% following Q2 earnings and a price target increase from BTIG, and Cognizant Technology Solutions rose 11.25% after reporting Q2 results, updating guidance, and affirming its dividend. On the losing side, Vertiv Holdings Co fell 17.26% after a mixed Q2, revenue short of guidance midpoint and a target cut, Nebius Group declined 12.65%, and Cerebras Systems dropped 12.11% despite a long-term data center colocation agreement announcement. Earnings will dominate the next few sessions, with Apple, Amazon, and Mastercard reporting on Thursday, and AbbVie, Moderna, ExxonMobil, and Chevron on Friday.

GE HealthCare Technologies shares rose about 9% in premarket trading after the company reported second-quarter 2026 results that beat expectations, helped by stronger services revenue and a $129 million benefit from tariff refunds. Revenue reached $5.3 billion, exceeding estimates by $40 million, with organic growth of about 4% year-over-year. Services sales grew roughly 8% to $1.88 billion, above the $1.83 billion analysts had forecast, while product revenue rose about 5% to $3.42 billion, slightly missing the $3.45 billion consensus. The company posted a book-to-bill ratio of 1.15 times, ahead of the 1.06 projected, and its net income margin improved by 90 basis points to 10.6%. Adjusted earnings per share came in at $1.13, beating the consensus by $0.09, as net income climbed 15% to $561 million. GE HealthCare maintained its full-year guidance for adjusted EPS of $4.80 to $5.00 and organic revenue growth of 3% to 4%.

Several companies made notable premarket moves following their latest quarterly reports. Biogen rose 0.7% after beating revenue consensus and raising its full-year adjusted EPS guidance. GE HealthCare Technologies surged 12% on second-quarter adjusted earnings per share of $1.13, topping the FactSet consensus of $1.04, and reaffirmed its 2026 earnings guidance. Ford Motor jumped 6% after beating adjusted earnings expectations and hiking its 2026 earnings outlook, though automotive revenue slightly missed LSEG estimates. Vertiv tumbled 13% as its 17.8% organic revenue growth fell well short of the 23.6% FactSet consensus. Generac gained 5.5% on adjusted earnings of $2.91 per share, beating the $2.01 forecast, and reiterated its revenue growth guidance. Procter & Gamble dropped over 3% after fiscal fourth-quarter revenue of $21.2 billion missed the $21.38 billion LSEG estimate, and net income fell to $3.04 billion from $3.62 billion a year ago. Deutsche Bank rose more than 2% after posting a record second-quarter after-tax profit of 1.9 billion euros. CoStar tumbled 15% on a revenue miss and current-quarter guidance of $935 million to $945 million, below the $967.5 million consensus. Rocky Brands surged 16% as adjusted earnings per share more than tripled year-over-year, aided by tariff refunds and strong double-digit growth in several brands. KLA Corp slid 7% after issuing disappointing guidance, while Seagate Technology rose 6% on an outlook that trounced expectations, and Western Digital gained 4% in sympathy. Manhattan Associates climbed 11% after beating estimates and raising full-year forecasts. Visa lost 2% as its 2026 guidance underwhelmed, and it announced plans to cut about 2,600 jobs. Teradyne surged 9% on beats across second-quarter results and third-quarter forecasts. NXP Semiconductors lost 1.7% as its third-quarter adjusted earnings guidance bracketed the LSEG estimate. Skyworks Solutions slumped 9% after adjusted margin of 44.9% narrowly missed the 45.0% expectation.

GE HealthCare Technologies reported second-quarter 2026 non-GAAP earnings of $1.13 per share, beating analyst estimates by $0.09, while revenue of $5.3 billion exceeded expectations by $40 million. Revenue grew 5.7% year-over-year, including organic revenue growth of 3.5%, driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions with overall strength in the U.S., Europe, the Middle East and Africa, and Rest of World, though Patient Care Solutions continued to be challenged. The company posted record organic orders growth of 11.1%, a book-to-bill ratio of 1.15 times, and a backlog of $23.9 billion. For the full year 2026, GE HealthCare reaffirmed its guidance, including organic revenue growth of 3.0% to 4.0%, adjusted EBIT margin of 15.4% to 15.7%, and adjusted EPS in the range of $4.80 to $5.00, representing 4.6% to 9.0% growth year-over-year. Shares rose 1% in pre-market trading.

GE HealthCare Technologies posted preliminary second-quarter 2026 results that beat management's prior expectations, with total revenue of $5.295 billion representing a 5.7% year-over-year increase and organic revenue growth of 3.5%. The company also announced that Chief Financial Officer James Saccaro will step down on August 14, with Controller and Chief Accounting Officer George Newcomb named interim CFO. GE HealthCare reaffirmed its full-year 2026 outlook, including organic revenue growth of 3% to 4%, Adjusted EPS of $4.80 to $5.00, and an Adjusted EBIT margin between 15.4% and 15.7%. Hedge fund data showed 60 funds held stakes in the company in the second quarter, up from 48 in the first quarter, indicating growing institutional confidence.

United Imaging Intelligence, an AI-focused subsidiary of Chinese medical technology giant Shanghai United Imaging Healthcare, is taking a cautious approach to deploying AI tools, resisting pressure for an aggressive rollout. Co-CEO Zhou Xiang, speaking on the sidelines of the World Artificial Intelligence Conference, said the company is not that extreme, noting that software engineers and architects warned him about potential side effects because the technology remains insufficiently mature. He added that in healthcare and medicine, the first mover advantage is not as drastic as in other fields. The United Imaging group competes with GE HealthCare, Siemens Healthineers and Philips in medical imaging and scanning equipment.

Catholic Health and GE HealthCare have entered a 10-year strategic partnership valued at approximately $500 million to modernize technology across Catholic Health's Long Island network. The Care Alliance will add more than 1,300 pieces of equipment spanning CT, PET/CT, MR, mammography, ultrasound, and other modalities to six hospitals and 36 other sites, with roughly half of the additions arriving in the first three years. The agreement includes AI-powered tools for scheduling, diagnostics, and monitoring, as well as a 10-year multivendor service component covering maintenance and lifecycle management across over 40 locations. The partnership aims to expand access to advanced imaging and specialized care in cardiology, oncology, neurology, and women's health, with patients expected to see benefits within the first year.

GE HealthCare Technologies is under fresh valuation scrutiny following a new research collaboration with Mayo Clinic on the MI-BET theranostics trial for advanced prostate cancer. The stock has fallen 13.66% over the past 90 days to a recent price of US$63.20, with a one-year total shareholder return decline of 16.09%, amid slower reported order growth and sector concerns after HCA Healthcare's update on surgery volumes. The most followed narrative points to a fair value of US$79.72, implying the stock is 20.7% undervalued, anchored in long-term earnings and margin assumptions driven by a pipeline of products including Radiopharmaceuticals, Total Body PET, and Photon Counting CT. However, the company still faces tariff and China regulatory risks, and any stumble in new product execution could challenge the undervaluation story.

GE HealthCare and Mayo Clinic have announced a research collaboration to advance personalized cancer treatment through the MI-BET study, which will evaluate whether imaging, blood-based biomarkers, and clinical data can tailor radioligand therapy for patients with advanced prostate cancer. The study will use GE HealthCare's StarGuide SPECT/CT platform and MIM Software's MIM LesionID Pro to monitor tumor response, aiming to determine if data-driven insights can guide decisions such as pausing or adapting therapy. Mayo Clinic has also become the first U.S. site to investigate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, which has CE Mark certification but is not yet approved for commercial sale in the United States. The collaboration is expected to strengthen GE HealthCare's position in the theranostics market, which is projected to grow from $11.50 billion in 2026 to approximately $31.38 billion by 2035. GE HealthCare shares have traded flat since the announcement on July 8 and are down 21.2% year-to-date.

The global AI in ultrasound imaging market is projected to grow from $1.28 billion in 2025 to $2.23 billion by 2030, at a compound annual growth rate of 11.8%. This growth is driven by increasing demand for point-of-care diagnostics, advancements in machine learning algorithms, and the rising prevalence of cancer. Key players include Samsung Electronics, Intel Corporation, IBM, NVIDIA, and Siemens Healthineers, which launched the portable AI-powered Acuson Maple system in November 2023. GE HealthCare strengthened its ultrasound offerings through the acquisition of Caption Health in February 2023. North America led the market in 2025, while Asia-Pacific is expected to witness the fastest growth during the forecast period.

GE HealthCare Technologies announced a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026. The dividend is payable on August 14, 2026, to shareholders of record as of July 24, 2026. The declaration was made by the company's Board of Directors.

GE HealthCare Technologies announced Allia platform upgrade pathways to modernize select legacy Innova and Discovery Image Guiding Solutions systems. The upgrades provide access to the latest Allia technologies and AI-enabled workflows while preserving existing infrastructure, reducing the need for major construction and minimizing disruption to clinical operations. New capabilities include CleaRecon DL for improved cone beam CT image quality, 3DStent for intraprocedural coronary stent visualization, and the OmnifyXR Interventional Suite augmented reality guidance solution. Healthcare providers can also access the AVVIGO+ intravascular imaging platform and AI-driven service options like Tube Watch and OnWatch Predict to reduce unplanned downtime. The initiative aims to help health systems manage growing procedural complexity and rising patient volumes without full system replacements.

The global AI in medical devices market is projected to grow from $16.16 billion in 2026 to $42.43 billion by 2030, at a compound annual growth rate of 27.3%. This expansion is driven by AI integration into clinical workflows, investments in smart healthcare infrastructure, and the rise of remote patient monitoring. Personalized medicine is a key growth driver, with the FDA approving 16 new personalized therapies for rare diseases in 2023. Strategic collaborations are accelerating innovation, such as Medtronic's partnership with NVIDIA to develop an AI platform for medical devices and GE HealthCare's $3 billion acquisition of Caption Health. North America led the market in 2025, while tariffs have spurred local manufacturing and regional supply chain development.

The global neonatal infant care market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a compound annual growth rate of 7.9 percent. Thermoregulation devices, including incubators and radiant warmers, held the largest product segment share in 2025 due to their critical role in preventing hypothermia in premature infants. North America led the market, supported by advanced healthcare infrastructure and a high concentration of Level III and IV NICUs, while the Asia Pacific region is expected to see the fastest growth driven by high preterm birth rates and expanding healthcare investments. Key players include GE HealthCare Technologies, Drägerwerk, Philips Healthcare, Natus Medical, and Fisher & Paykel Healthcare. Recent developments include Dräger Medical's launch of the BabyRoo TN 300 open warmer with enhanced thermoregulation and monitoring features.

GE HealthCare Technologies plans to showcase new cloud-enabled enterprise imaging solutions at the SIIM 2026 Annual Meeting, focusing on cloud-based imaging workflows and data management for healthcare providers. The presentation highlights ongoing product development in medical imaging technology ahead of broader commercial adoption. The company's stock is trading at $65.76, down 20.6% year to date and 11.4% over the past year, despite a 6.8% gain over the past week. The cloud-enabled imaging push aligns with GE HealthCare's strategy to expand digital solutions and recurring software revenue, though execution risks and competition from Siemens Healthineers and Philips remain. Investors will watch for concrete signals such as signed enterprise imaging contracts and adoption by large health systems to gauge whether this becomes a driver of long-term revenue mix.

RBC Capital initiated coverage of GE HealthCare Technologies with an Outperform rating and an $80 price target on June 23. The analyst cited an attractive risk-reward profile, stronger R&D spending, and improved commercial execution since the company's 2023 separation from General Electric, along with a solid order backlog expected to support faster growth later in 2026. Separately, on June 9, GE HealthCare announced it will showcase its latest cloud-enabled enterprise imaging technologies, including the Genesis Radiology Workspace and InteleShare, at the SIIM 2026 Annual Meeting.

The Fourth China International Supply Chain Expo has opened its Healthy Life Chain section, drawing more than 100 leading companies across Medical Technology, Quality Living, and Heritage Wellness zones. Global players GE Healthcare and Siemens Healthineers are demonstrating full China-for-China R&D and manufacturing capabilities, while AstraZeneca features an AI-powered drug discovery platform. Chinese innovators including BGI with a human genome foundation model and Longwood Valley with a domestically produced orthopedic surgical robot are also taking center stage. In consumer health, Procter & Gamble, L'Oréal, Panasonic, and Starbucks are showcasing digital intelligence and sustainability in their supply chains, with Starbucks connecting directly to Yunnan coffee farms for full traceability. Chinese TCM brands such as Guangzhou Phar. Holdings, Xin Bao Tang, and Zhendong Pharmaceutical are accelerating global expansion and vertical integration of authentic herb supply chains, alongside AI-driven diagnostic tools like smart pulse-taking devices.

GE HealthCare Technologies is advancing its healthcare technology lead by highlighting new AI-driven imaging solutions at two major medical meetings. At the Society for Imaging Informatics in Medicine 2026 Annual Meeting, the company presented its Genesis Radiology Workspace and cloud-based offerings from its Intelerad unit, including InteleShare. At the 2026 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, GE HealthCare showcased imaging innovations and AI workflow tools aimed at supporting theranostics and rising radiopharmaceutical use. The company is focused on improving productivity, expanding access to advanced diagnostics, and enhancing clinical decision-making as nuclear medicine moves toward broader adoption.

US stock futures pointed lower on Wednesday, with E-mini S&P 500 contracts down about 1.5% and Nasdaq-100 futures weaker by more than 2.7%, as investors weighed the prospect of a Federal Reserve rate hike in September and soft global growth. The US 10-year Treasury yield sat near 4.5%, raising borrowing costs for households and businesses, while Europe's latest purchasing manager indexes showed services activity shrinking and manufacturing only edging ahead. Among individual movers, Axon Enterprise surged 5.61%, GE HealthCare Technologies gained 5.08% after RBC initiated coverage with an Outperform rating, and International Business Machines climbed 5.04% following an upgrade to Overweight. On the losing side, Sandisk declined 13.64%, Micron Technology fell 13.18% ahead of its closely watched earnings report, and Vertiv Holdings dropped 11.07% as recent gains in data center cooling stocks reversed. Key events on the radar include Micron's Q3 results, NVIDIA's Annual General Meeting, and Paychex's Q4 numbers, all on Wednesday, with the Fed rate path focus centering on PCE data and 10-year yields through Friday.